Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GreeceBack to Greece

Clinical trials in Filothei

16 clinical trials in Filothei, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

Filothei at a glance
16
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

16 trials in Filothei

Open in trial search

Ovarian cancer recurrent

Recruiting

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Systemic scleroderma

Recruiting

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

HER2 positive endometrial cancer

Recruiting

Study of Trastuzumab Deruxtecan Versus Chemotherapy as Additional Treatment After Surgery for Patients with HER2-Positive Endometrial Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Breast cancer+2

Recruiting

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Capivasertib
  • Sponsor:Relay Therapeutics Inc.

Endometrial cancer+1

Recruiting

A study comparing BNT323 with chemotherapy in patients with HER2-expressing recurrent endometrial cancer who received previous treatment

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:DB-1303
  • Sponsor:BioNTech SE

Breast cancer+2

Recruiting

Study of PF-07248144 and fulvestrant in adults with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who had progression after CDK4/6 inhibitor therapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Endometrial cancer

Recruiting

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Lennox-Gastaut syndrome

Recruiting

Study on Carisbamate for Treating Seizures in Children and Adults with Lennox-Gastaut Syndrome

Investigational
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Carisbamate
  • Sponsor:Sk Life Science Inc.

Fallopian tube cancer+1

Not yet recruiting

Study of Mirvetuximab Soravtansine and Bevacizumab for Maintenance in Adults with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

A Study of Camizestrant Compared to Standard Hormone Therapy for Patients with ER-Positive HER2-Negative Early Breast Cancer After Initial Treatment

Not recruiting
Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:AstraZeneca AB

Duchenne muscular dystrophy

Not recruiting

Study on Eteplirsen for Patients with Duchenne Muscular Dystrophy with Deletion Mutations Amenable to Exon 51 Skipping

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Eteplirsen
  • Sponsor:Sarepta Therapeutics Inc.

Other cities in Greece

The busiest research cities in the country

All 50 cities in Greece

Clinical research in Filothei

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on platinum-sensitive ovarian cancer and advanced breast cancer treatments, evaluating new combination therapies and maintenance approaches.

  • Ovarian, Fallopian Tube, and Peritoneal Cancers
  • HER2-Positive Breast Cancer
  • Estrogen Receptor-Positive Breast Cancer

Multiple studies examining targeted therapies and novel drug combinations to improve patient outcomes.

02 Neurological Disorders

Research initiatives targeting rare neurological conditions, including studies on Lennox-Gastaut syndrome and innovative treatments for seizure management.

  • Seizure Disorders
  • Neuromuscular Conditions
  • Pediatric Neurological Disorders

Focused on developing new therapeutic approaches for complex neurological conditions.

03 Rare Diseases

Specialized research programs investigating treatments for Duchenne muscular dystrophy, exploring novel therapeutic approaches and dosing strategies.

  • Genetic Disorders
  • Progressive Muscle Conditions
  • Pediatric Rare Diseases

Evaluating innovative treatments to address unmet medical needs in rare disease populations.

Back to GreeceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.